The company
Cardiol Therapeutics Inc. - Class A Common Shares
CRDL · Nasdaq
CRDL stood above a rising 150-day average in 19 of the last 52 weekly readings, and has been out of that trend for the last 3 weeks. It is 20.9% below that average now. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).
Statistics
- Rotation
- Not moving yet
- Weeks in an uptrend
- out for 3
- Industry in uptrend
- 16% -15 in 4 wk
- Insider buys, 12 months
- $0
- Insider sales, 12 months
- $0
- Officials’ trades on record
- 0
- Institutions holding
- 49 (+5)
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 19 of 52 weeks.
Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.
Money in and out
Open-market buys above the line and sales below, in dollars.
Congress and officials
No member of Congress or official has disclosed a trade in it.
Insiders
No open-market buy or sale by its insiders on record.
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|---|---|
| MMCAP International Inc. SPCadded · filed 14 Aug 2026 | 15,598,560$16.5M | +246,243+1.6% |
| Tejara Capital Ltdreduced · filed 11 Aug 2026 | 5,113,822$5.4M | -16,300−0.3% |
| Ikarian Capital, LLCadded · filed 14 Aug 2026 | 3,325,000$3.5M | +600,000+22.0% |
| BOOTHBAY FUND MANAGEMENT, LLCadded · filed 14 Aug 2026 | 975,721$1.0M | +180,840+22.8% |
| CITADEL ADVISORS LLCreduced · filed 14 Aug 2026 | 796,529$844K | -23,375−2.9% |
| RENAISSANCE TECHNOLOGIES LLCadded · filed 13 Aug 2026 | 772,837$819K | +543,031+236.3% |
| TWO SIGMA INVESTMENTS, LPadded · filed 14 Aug 2026 | 746,937$792K | +212,726+39.8% |
| INTEGRITY ALLIANCE, LLC.reduced · filed 31 Jul 2026 | 388,492$412K | -76,533−16.5% |
| MORGAN STANLEYadded · filed 13 Aug 2026 | 355,030$376K | +104,609+41.8% |
| GOLDMAN SACHS GROUP INCadded · filed 14 Aug 2026 | 333,900$354K | +1,500+0.5% |
News
No headline names it lately.
Everyone who traded it
Nobody on record has traded it.
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.